Clinical trials
Resectable Pancreatic Adenocarcinoma clinical trials
Below are recruiting resectable pancreatic adenocarcinoma clinical trials, each written for real people, not researchers. We’re tracking 171 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06229496RecruitingPhase 1
Study of GAS for newly diagnosed advanced pancreatic cancer
This trial tests an oral medication called GAS in people with pancreatic cancer that has spread to other parts of the body, who have not yet received any treatment for metastatic disease. The goal is to find the best dose and see how well it works.
Chiayi CityAges 18 years+ - NCT04926467RecruitingPhase 2
Chemo plus anakinra for pancreatic cancer
This Phase 2 study tests whether adding anakinra (an immune signal blocker) to standard chemotherapy can improve outcomes for some people with pancreatic ductal adenocarcinoma. It’s mainly for adults with stage I–III disease who have enough organ function and are able to come in for treatment and follow-up.
Dallas, TexasAges 18 years+ - NCT05529940RecruitingPhase 3
FOLFIRINOX around surgery for resectable pancreatic cancer
This trial compares giving chemotherapy with FOLFIRINOX before and after surgery versus giving it mainly after surgery for people with resectable pancreatic duct cancer. It aims to improve outcomes by timing the treatment around the operation.
SeoulAges 19–80 - NCT06966440Recruiting
MRD-Guided Chemotherapy After Pancreatic Cancer Surgery
This trial tests whether using a special blood test (MRD) to guide chemotherapy after pancreatic cancer surgery can improve outcomes. It is for people who have had their cancer completely removed and are ready for standard follow-up therapy.
ShanghaiAges 18–75 - NCT06790602RecruitingPhase 2
Cemiplimab plus gemcitabine for metastatic pancreatic cancer
This trial tests a combination of an immunotherapy drug (cemiplimab) and chemotherapy (gemcitabine) for people with pancreatic cancer that has spread to other parts of the body. It is for those whose tumors have specific genetic changes (in the SWI/SNF genes) and have only had one prior treatment that was not immunotherapy.
La Jolla, CaliforniaAges 18 years+ - NCT06896188RecruitingPhase 1
Study of 9-ING-41 and retifanlimab plus chemo for advanced pancreatic cancer
This trial tests a new combination of two experimental drugs (9-ING-41 and retifanlimab) plus a standard chemotherapy regimen (modified FOLFIRINOX) for people with advanced or metastatic pancreatic cancer who have not yet received treatment for their advanced disease. The goal is to see if this combination is safe and effective.
Pittsburgh, PennsylvaniaAges 18 years+ - NCT07481383RecruitingPhase 1
Implant device for chemo delivery in advanced pancreatic cancer
This trial tests an implantable device that delivers chemotherapy (gemcitabine) directly to pancreatic tumors. It may offer a new treatment option for people with non-metastatic, advanced pancreatic cancer that cannot be surgically removed.
Ann Arbor, MichiganAges 18 years+ - NCT06349278Recruiting
Surgery for pancreatic cancer with limited liver spread after chemo
This trial is for people with pancreatic cancer that has spread to the liver (3 spots or fewer). It tests whether removing both the original tumor and the liver spots after a specific chemotherapy (FOLFIRINOX) can be helpful. You may be eligible if the chemo shrinks the tumors enough and you are healthy enough for surgery.
Québec, QuebecAges 18 years+ - NCT07163273RecruitingPhase 2
Alternating chemotherapy for first-line metastatic pancreatic cancer
This study tests a monthly rotation of two chemotherapy combinations (NALIRIFOX and GnP) as the first treatment for metastatic pancreatic cancer. The goal is to see if alternating the drugs helps control the cancer while reducing side effects.
Bay Shore, New YorkAges 18 years+ - NCT06048484RecruitingPhase 2
Combination therapy for localized pancreatic cancer
This trial tests a combination of drugs for people with localized pancreatic cancer who have already completed 8 cycles of modified FOLFIRINOX chemotherapy before surgery. The goal is to see if adding these drugs after chemo and radiation helps improve outcomes.
Lake Success, New YorkAges 18 years+ - NCT05802407Recruiting
ctDNA blood test monitoring after pancreatic cancer surgery
This study looks at whether a special blood test (ctDNA) can detect tiny amounts of pancreatic cancer left after surgery. It may help doctors monitor who is at higher risk of cancer coming back, so they can tailor follow-up and treatment timing.
BeijingAges 18 years+ - NCT06831136RecruitingPhase 2
Endoscopic ultrasound ablation plus immunotherapy for pancreatic cancer
This trial tests a combination of endoscopic ultrasound-guided heat ablation (RFA) and the immunotherapy drug pembrolizumab for people with locally advanced or metastatic pancreatic cancer that cannot be surgically removed. The goal is to see if this approach can shrink tumors and improve outcomes.
Houston, TexasAges 18 years+ - NCT06381882Enrolling by invitation
Human microbiome study after pancreatic surgery
This study looks at how tiny organisms in your gut (the microbiome) affect recovery after surgery for pancreatic cancer or related growths. It may help doctors understand how to improve outcomes for future patients.
NieuwegeinAges 18 years+ - NCT04998552Recruiting
CyberKnife radiation for certain pancreatic cancer patients after chemotherapy
This trial studies how safe CyberKnife is when used to treat some borderline resectable or locally advanced pancreatic cancers after chemotherapy. It may help patients by targeting the tumor with precise radiation, while researchers closely watch for side effects.
Pennington, New JerseyAges 18 years+ - NCT06141031RecruitingPhase 1
TTI-101 plus radiation for borderline or locally advanced pancreatic cancer
This trial tests a new oral drug (TTI-101) combined with targeted radiation (SBRT) for people with pancreatic cancer that is not removable by surgery. It aims to see if this combination helps shrink tumors that are borderline resectable or locally advanced.
Aurora, ColoradoAges 18 years+ - NCT04789486RecruitingPhase 1/Phase 2
MR-guided radiation plus nanoparticles for central lung or pancreatic tumors
This early-phase study tests a new way to deliver focused radiation using MRI guidance and tiny particles, aiming to treat certain central lung tumors or locally advanced pancreatic cancer. It’s designed to see how safe it is and how well it can control these tumors.
Boston, MassachusettsAges 18 years+ - NCT06182072RecruitingPhase 1
ProAgio for advanced pancreatic cancer
This trial tests a new drug called ProAgio combined with standard chemotherapy for people with stage IV pancreatic cancer. It aims to see if the combination is safe and effective.
Birmingham, AlabamaAges 18 years+ - NCT05851924RecruitingPhase 2
Nalirifox plus radiation for nonmetastatic pancreatic cancer
This trial studies Nalirifox (chemotherapy) given together with radiation therapy for pancreatic ductal adenocarcinoma that has not spread to distant organs. It may help shrink the cancer and improve local control, especially when surgery is not an option right now.
Basking Ridge, New JerseyAges 18 years+ - NCT05919238RecruitingPhase 1
Padeliporfin treatment for non-removable pancreatic cancer
This Phase 1 study tests a new cancer treatment called padeliporfin given through a special catheter to treat pancreatic ductal adenocarcinoma that cannot be removed by surgery. It aims to see how safe the treatment is and whether it can help control the tumor in people who are not surgical candidates.
Duarte, CaliforniaAges 18 years+ - NCT05679583RecruitingPhase 2
Pre-surgery focused radiation for resectable pancreatic cancer
This trial studies giving highly targeted radiation before surgery for patients with operable pancreatic cancer. The goal is to shrink or control the cancer before an operation while keeping side effects manageable.
SeoulAges 20 years+ - NCT07022015Recruiting
Predicting pancreatic leak after pancreatic surgery
This trial looks at factors that can predict a serious complication called a pancreatic fistula (a leak from the pancreas) after a Whipple procedure. The goal is to help doctors better understand and manage this risk.
MinyaAges 18–75 - NCT06944587Recruiting
Personalized care for advanced pancreatic cancer
This trial is testing a new way to treat pancreatic cancer that has spread to nearby tissues but not to distant organs. It uses a tailored plan that may include chemotherapy and possibly surgery. The goal is to see if this personalized approach helps people live longer and better.
Bergen, NorwayAges 18 years+ - NCT07240766RecruitingPhase 2
New drug combo for KRAS G12D pancreatic cancer
This trial tests a new targeted drug (HRS-4642) combined with another drug (Nimotuzumab) and two chemotherapy drugs for people with a specific type of pancreatic cancer that has a KRAS G12D mutation. The goal is to see if this combination can help make the tumor smaller and possibly removable by surgery.
Hangzhou, ZhejiangAges 18–75 - NCT07157033RecruitingPhase 1/Phase 2
Testing XER-001 with radiation for advanced pancreatic cancer
This trial tests a new way to deliver a drug called amifostine (XER-001) alongside intense radiation therapy (SBRT) for people with locally advanced pancreatic cancer that can't be surgically removed. The goal is to see if it's safe and effective at protecting healthy tissue while targeting the tumor.
Duarte, CaliforniaAges 18 years+
Hear when a new Resectable Pancreatic Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for resectable pancreatic adenocarcinoma?
- Yes. Clin2 currently lists 171 recruiting resectable pancreatic adenocarcinoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a resectable pancreatic adenocarcinoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a resectable pancreatic adenocarcinoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Borderline Resectable Pancreatic Adenocarcinoma
- Borderline Resectable Pancreatic Ductal Adenocarcinoma
- Resectable Pancreatic Ductal Adenocarcinoma
- Pancreatic Ductal Adenocarcinoma
- Pancreatic Ductal Adenocarcinoma (PDAC)
- Pancreatic Adenocarcinoma
- Metastatic Pancreatic Adenocarcinoma
- Pancreatic Cancer Resectable
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.